Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Liora M. Schultz
Consulting or Advisory Role: Novartis
Jenna Rossoff
Consulting or Advisory Role: Novartis
Christa Krupski
Employment: US Acute Care Solutions (I)
Stock and Other Ownership Interests: US Acute Care Solutions (I)
Travel, Accommodations, Expenses: US Acute Care Solutions (I)
Christine L. Phillips
Consulting or Advisory Role: Novartis, Incyte
Julie-An Talano
Consulting or Advisory Role: Novartis
Susanne H.C. Baumeister
Employment: Takeda (I)
Stock and Other Ownership Interests: Takeda (I), AstraZeneca (I)
Gary Douglas Myers
Honoraria: Novartis
Consulting or Advisory Role: Novartis
Speakers' Bureau: Novartis
Research Funding: Novartis (Inst)
Patrick A. Brown
Consulting or Advisory Role: Novartis, Jazz Pharmaceuticals, Servier, Kite, a Gilead Company, Amgen, Kura Oncology, Takeda
Muna Qayed
Honoraria: Novartis, Vertex
Consulting or Advisory Role: Novartis
Travel, Accommodations, Expenses: Novartis
Michelle Hermiston
Stock and Other Ownership Interests: Gladiator Biosciences (I), Coagulant Therapeutics (I)
Consulting or Advisory Role: Novartis, Sobi, KaliVir Immunotherapeutics (I)
Patents, Royalties, Other Intellectual Property: Spouse has patents pending for platform technology with application to oncology, diagnostics, and anti-infections and for antibleeding technology (I)
Prakash Satwani
Consulting or Advisory Role: Takeda
Speakers' Bureau: SOBI
Open Payments Link: https://openpaymentsdata.cms.gov/physician/1047592
Rachel Wilcox
Research Funding: Novartis (Inst), AlloVir (Inst)
Travel, Accommodations, Expenses: Novartis
Vanessa A. Fabrizio
Consulting or Advisory Role: Adaptimmune
Crystal L. Mackall
Leadership: Syncopation Life Sciences
Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Biopharma, Apricity Health, Syncopation Life Sciences, Ensoma, Mammoth Biosciences
Consulting or Advisory Role: Vor Biopharma, Apricity Health, Alimera Sciences, PACT Pharma, Nektar, Lyell Immunopharma, NeoImmuneTech, Syncopation Life Sciences, NeoImmuneTech, Bristol Myers Squibb, Immatics, GlaxoSmithKline, Ensoma, Mammoth Biosciences
Research Funding: Lyell Immunopharma
Patents, Royalties, Other Intellectual Property: I am an inventor on numerous patents related to chimeric antigen receptor therapeutics and received royalties from NIH for the CD22-CAR patent licensed to Juno therapeutics
Travel, Accommodations, Expenses: NeoImmuneTech, Roche, Nektar
Other Relationship: Lyell Immunopharma, Syncopation Life Sciences
Kevin J. Curran
Honoraria: Novartis
Consulting or Advisory Role: Novartis, Mesoblast
Research Funding: Juno Therapeutics, Celgene (Inst), Novartis (Inst), Cellectis (Inst)
Michael R. Verneris
Stock and Other Ownership Interests: Fate Therapeutics
Honoraria: Novartis, Jazz Pharmaceuticals
Patents, Royalties, Other Intellectual Property: patent to make innate lymphoid cells. It is not licensed, patent for CAR T-cell homing
Theodore W. Laetsch
Stock and Other Ownership Interests: Advanced Microbubbles
Consulting or Advisory Role: Novartis, Bayer, Cellectis, Aptitude Health, Clinical Education Alliance, Deciphera, Jumo Health, Massive Bio, Med Learning Group, Medscape, Physicians' Education Resource, Y-mAbs Therapeutics, AI Therapeutics, Jazz Pharmaceuticals, GentiBio, Menarini, Pyramid Biosciences
Research Funding: Pfizer (Inst), Novartis (Inst), Bayer (Inst), AbbVie (Inst), Amgen (Inst), Atara Biotherapeutics (Inst), Bristol Myers Squibb (Inst), Lilly (Inst), Epizyme (Inst), GlaxoSmithKline (Inst), Janssen (Inst), Jubilant Pharmaceuticals (Inst), Novella Clinical (Inst), Servier (Inst), Foundation Medicine (Inst), Merck Sharp & Dohme (Inst), Turning Point Therapeutics (Inst)
Heather Stefanski
Honoraria: Novartis
No other potential conflicts of interest were reported.
留言 (0)